Next 10 |
Revenues at € 781.6 million in 1Q24, +6.0% Y/Y EBITDA at € 361.7 million in 1Q24, +8.6% Y/Y, with c. +112 bps EBITDA margin expansion 2024 Guidance confirmed Up to € 500 million share buy-back program launched today Th...
Rome becomes the first European city to offer open loop transit payments to JCB Cardmembers TOKYO & LONDON, May 8, 2024 - (JCN Newswire) - Boarding public transport and pay the fare by simply tapping with a contactless payment card on turnstiles or authorized readers: Rome is th...
2024-04-05 14:55:10 ET More on mid-day movers & stock 22nd Century Group, Inc. (XXII) Q4 2023 Earnings Call Transcript Grindrod Shipping: Favorable Outlook, M&A Completion, And Very Cheap Grindrod Shipping: When A Young Fleet And Healthy Financials Are Not En...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
2024-03-07 09:09:27 ET CERo Therapeutics ( CERO ) +625% after announces publication of preclinical research supporting the use of its clinical candidate CER-1236 to treat AML patients . Lytus Technologies ( LYT ) +210% after enters $326 billion data center market...
2023 guidance delivered Revenues at € 3,361.7 million in FY23, +7.0% Y/Y EBITDA at € 1,751.8 million in FY23, +10.0% Y/Y, with c. +146 bps EBITDA margin expansion Strong Excess cash generation growth, at more than € 600 million in F...
GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today...
2024-02-05 08:25:25 ET More on pre-market losers & stocks. Livent: Undervalued With Significant Upside Potential Livent: Wonderful Company Fairly Valued Livent And Albemarle: 2 Lithium Stocks To Buy Now Livent and Allkem shareholders approve merger of equ...
2024-02-02 14:54:54 ET More on Neximmune Financial information for Neximmune Read the full article on Seeking Alpha For further details see: NexImmune slips after securities offering
GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today...
News, Short Squeeze, Breakout and More Instantly...
NexImmune Inc. Company Name:
NEXI Stock Symbol:
NASDAQ Market:
Revenues at € 781.6 million in 1Q24, +6.0% Y/Y EBITDA at € 361.7 million in 1Q24, +8.6% Y/Y, with c. +112 bps EBITDA margin expansion 2024 Guidance confirmed Up to € 500 million share buy-back program launched today Th...
Rome becomes the first European city to offer open loop transit payments to JCB Cardmembers TOKYO & LONDON, May 8, 2024 - (JCN Newswire) - Boarding public transport and pay the fare by simply tapping with a contactless payment card on turnstiles or authorized readers: Rome is th...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...